Amedisys (AMED) Stock Price, News & Analysis

Company Overview

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Key Stats

• Today's Range: $100.93 to $101.02
• 50-Day Range: $95.96 to $101.01
• 52-Week Range: $82.15 to $101.02
• Volume: 1.06 million shs
• Average Volume: 780,222 shs
• Market Capitalization: $3.32 billion
• P/E Ratio: 39.30
• Dividend Yield: N/A
• Price Target: $100.50
• Consensus Rating: Moderate Buy

Amedisys Stock Analysis - MarketRank™

Amedisys scored higher than 60% of companies evaluated by MarketBeat, and ranked 397th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Amedisys has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Amedisys has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.00%

Earnings Growth

Earnings for Amedisys are expected to grow by 10.00% in the coming year, from $4.40 to $4.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amedisys is 39.30, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amedisys is 39.30, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.41.

Price to Earnings Growth Ratio

Amedisys has a PEG Ratio of 1.34. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Amedisys has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.96% of the float of Amedisys has been sold short.

Short Interest Ratio / Days to Cover

Amedisys has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Amedisys has recently increased by 42.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amedisys does not currently pay a dividend.

Dividend Growth

Amedisys does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 5.0 / 5
• Environmental Score: -0.61

Percentage of Shares Shorted

9.96% of the float of Amedisys has been sold short.

Short Interest Ratio / Days to Cover

Amedisys has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Amedisys has recently increased by 42.86%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.30

News Sentiment

Amedisys has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Amedisys this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for AMED on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

1 people have added Amedisys to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amedisys insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Amedisys is held by insiders.

Percentage Held by Institutions

94.36% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AMED Stock Analysis - Frequently Asked Questions

How have AMED shares performed this year?

Amedisys' stock was trading at $90.79 at the beginning of 2025. Since then, AMED stock has increased by 11.3% and is now trading at $101.01.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) issued its quarterly earnings results on Tuesday, July, 29th. The health services provider reported $1.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.39 by $0.15. The business's revenue was up 5.2% on a year-over-year basis.

Who are Amedisys' major shareholders?

Top institutional shareholders of Amedisys include Alpine Associates Management Inc. (3.34%), State Street Corp (3.25%), Norges Bank (2.74%) and Qube Research & Technologies Ltd (2.40%).
View institutional ownership trends.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amedisys investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/26/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Health Care Services
• Current Symbol: NASDAQ:AMED
• CIK: 896262
• Web: www.amedisys.com
• Phone: (225) 292-2031
• Fax: 225-292-8163
• Employees: 19,000
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Amedisys: $100.50
• High Price Target: $101.00
• Low Price Target: $100.00
• Potential Upside/Downside: -0.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.57
• Trailing P/E Ratio: 39.30
• Forward P/E Ratio: 22.96
• P/E Growth: 1.34
• Net Income: $43.23 million
• Net Margins: 3.56%
• Pretax Margin: 6.21%
• Return on Equity: 12.91%
• Return on Assets: 7.29%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 1.36
• Quick Ratio: 1.36

Sales & Book Value

• Annual Sales: $2.40 billion
• Price / Sales: 1.38
• Cash Flow: $6.24 per share
• Price / Cash Flow: 16.20
• Book Value: $38.77 per share
• Price / Book: 2.61

Miscellaneous

• Outstanding Shares: 32,887,000
• Free Float: 32,196,000
• Market Cap: $3.32 billion
• Optionable: Optionable
• Beta: 0.89